Skip to main content

Table 2 Dark and light-adapted ERG responses at baseline and 12-week study visits

From: Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial

ERG stimulus

Measurement

Baseline

Follow-up

P (Paired t-test)

DA—0.01

b-wave amplitude (µV)

195.6 ± 37.0

214.6 ± 28.9

0.5313

 

b-wave implicit time (ms)

101.1 ± 3.7

102.1 ± 3.6

0.8158

DA—3.0

a-wave implicit time (ms)

23.2 ± 0.8

23.1 ± 0.8

0.9052

a-wave amplitude (µV)

148.3 ± 23.2

193.2 ± 23.7

0.1840

b-wave implicit time (ms)

65.3 ± 7.0

56.5 ± 1.4

0.2549

b-wave amplitude (µV)

371.6 ± 44.2

425.9 ± 36.5

0.1840

OP AUC (µV.ms)

483.9 ± 49.7

523.2 ± 117.5

0.5243

DA—10.0

a-wave implicit time (ms)

17.7 ± 1.0

18.0 ± 0.9

0.7324

a-wave amplitude (µV)

199.8 ± 27.8

233.9 ± 24.0

0.1511

b-wave implicit time (ms)

57.1 ± 1.8

60.5 ± 2.3

0.2353

b-wave amplitude (µV)

377.9 ± 47.4

457.3 ± 34.2

0.0667

LA—30 Hz

Latency (ms)

39.6 ± 6.9

47.3 ± 6.9

0.2107

Amplitude (µV)

89.2 ± 11.5

91.6 ± 9.1

0.7740

LA—3.0

a-wave implicit time (ms)

17.4 ± 0.3

18.0 ± 0.4

0.1107

a-wave amplitude (µV)

27.1 ± 3.7

28.8 ± 1.5

0.6047

b-wave implicit time (ms)

34.0 ± 0.5

34.4 ± 0.6

0.3966

b-wave amplitude (µV)

107.6 ± 15.6

111.5 ± 9.1

0.6936

  1. DA—0.01. Dark-adapted 0.01 ERG (a rod-driven ON bipolar cells response). DA—3.0. Dark-adapted 3 ERG (combined responses from photoreceptors and bipolar cells from rod and cone systems; rod dominated). Dark-adapted oscillatory potentials area under curve (OP AUC) (primarily from amacrine cells). DA—10.0. Dark-adapted 10 ERG (combined response with enhanced a-waves reflecting photoreceptor function). LA—30 Hz. Light-adapted 30 Hz flicker ERG (cone-pathway-driven response). LA—3.0. Light-adapted 3 ERG (a-waves from cone photoreceptors and cone OFF- bipolar cells; the b-wave are from ON- and OFF-cone bipolar cells)